如果你玩过电子游戏《死亡搁浅》，一定会对主角那身行头印象深刻。作为游戏设定的末世背景下 的"最强快递员"，他不仅能背着比自己体重沉好几倍的货物翻山越岭，还能与怪物近身肉搏。而之所以 能做到这一切，是因为他身上那套充满机械感的外骨骼。 如今，外骨骼已经从游戏走进了现实。在国内，八达岭长城、黄山、泰山、杭州半山国家森林公园、五 台山等多个景区均已引入外骨骼辅助登山租赁服务；在海外，美国、德国、日本等国的可穿戴设备公司 也纷纷推出了自己的明星产品。美国市场研究机构Grand View Research数据显示，2024年全球外骨骼市 场规模约为5亿美元，预计到2030年将达到12.5亿美元，复合年增长率超过16%。 不过，如果你以为穿上外骨骼就可以原地变身"超级英雄"，那绝对是想多了。别看游戏里穿着它能搬山 填海，现实里的它，更适合的场景或许是"遛弯"？ 实际上，外骨骼是一系列可穿戴机械装置产品的统称，按照应用场景可大体分为三类：其一为增强型外 骨骼，原理是通过电机、液压或气压驱动，为穿戴者提供额外力量，典型应用场景包括工业、物流或军 事用途；其二为康复型外骨骼，主要是通过预设程序或脑机接口控制金属构件，帮助行动障 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Nevada 99-0 ...

Exhibit 10.1 CONTRIBUTION AND EXCHANGE AGREEMENT BY AND AMONG EKSO BIONICS HOLDINGS, INC., E x h i b i t A: I n v e s t o r R i g h t s A g r e e m e n t E x h i b i t B: F o r m o f S t o c k P o w e r E x h i b i t C: R e s t a t e d I s s u e r B y l a w s E x h i b i t D: R e s t a t e d I s s u e r A r t i c l e s E x h i b i t E: 2 0 2 6 P l a n i i APPLIED DIGITAL CLOUD CORPORATION DATED AS OF FEBRUARY 14, 2026 TABLE OF CONTENTS | ARTICLE I. | | | | --- | --- | --- | | DEFINITIONS | | 2 | | | 1.1 Def ...

Core Viewpoint - Ekso Bionics Holdings, Inc. has entered into a private placement agreement to raise approximately $5.9 million through the sale of Series B Preferred Stock and warrants, aimed at enhancing its working capital and corporate purposes [1][3]. Group 1: Private Placement Details - The company will sell 5,852 shares of Series B Preferred Stock with a stated value of $1,000 per share, convertible into 711,922 shares of common stock at a conversion price of $8.22 per share [2]. - The warrants will allow the purchase of up to 355,960 shares of common stock at an exercise price of $8.22 per share, expiring five years from the initial exercise date [2]. - The closing of the private placement is expected around January 22, 2026, pending customary closing conditions [3]. Group 2: Financial Implications - The gross proceeds from the private placement are anticipated to be approximately $5.9 million before deducting fees and expenses [3]. - The net proceeds will be utilized for working capital and general corporate purposes [3]. Group 3: Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in medical and industrial applications [7]. - The company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [7].

Group 1 - The core focus of the news is the investigation by Monteverde & Associates PC into EKSO Bionics Holdings, Inc. regarding its merger with Applied Digital Cloud, which is expected to result in EKSO shareholders owning approximately 3% of the combined company [1] - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders [1] - The firm operates from the Empire State Building in New York City and emphasizes its successful track record in class action securities litigation [2][4] Group 2 - The firm invites shareholders of EKSO Bionics who have concerns or seek additional information to contact them for free [3] - Monteverde & Associates PC highlights its national presence and experience in trial and appellate courts, including the U.S. Supreme Court [2] - The firm provides a platform for shareholders to inquire about their rights and potential recovery options related to the merger [3][4]

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the merger between EKSO Bionics Holdings, Inc. and Applied Digital Cloud for EKSO shareholders [1][2]. Group 1: Investigation Details - The investigation focuses on whether EKSO and its board violated federal securities laws and/or breached fiduciary duties by not obtaining the best possible consideration for shareholders [2]. - The investigation also questions if EKSO disclosed all material information necessary for shareholders to adequately assess and value the merger [2]. Group 2: Potential Actions - On behalf of EKSO shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures, and other relief related to the proposed transaction [3]. - The legal action would be handled on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket legal fees or expenses [3]. Group 3: Firm Background - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4].

Core Viewpoint - Ekso Bionics Holdings, Inc. announced it will become the exclusive U.S. sales agent and distributor for MediTouch's BalanceTutor rehabilitation system, leading to a significant drop in its stock price by 12.75 percent to $3.97 [1] Group 1: Stock Performance - Ekso Bionics shares fell from a previous close of $4.5502 to $3.97, marking a decline of $0.5802 [1] - The stock opened at $4.25 and has traded within a range of $3.5100 to $4.4635 on the same day, with a trading volume of 5.05 million shares [2] - The company's 52-week stock price range is between $2.73 and $14.97 [2] Group 2: Product Announcement - The BalanceTutor rehabilitation system utilizes a patented 4D perturbation treadmill designed to simulate real-world balance challenges, enhancing patient safety and rehabilitation outcomes [1]

Core Insights - Ekso Bionics has entered into an agreement with MediTouch to become the exclusive authorized sales agent and distributor of the BalanceTutor rehabilitation system in the United States [1][3] Group 1: Product Overview - The BalanceTutor is a unique rehabilitation system featuring a patented 4D perturbation treadmill that allows patients with balance impairments to respond to unexpected disturbances while walking [2] - The treadmill can move in multiple directions (forward, backward, side-to-side) to simulate realistic balance challenges, ensuring patient safety through an overhead support frame [2] Group 2: Strategic Implications - The partnership with MediTouch is expected to enhance Ekso Bionics' market reach and align with its existing enterprise health exoskeleton solutions, targeting both inpatient and outpatient rehabilitation facilities [3] - The collaboration is seen as a significant milestone for MediTouch, aiming to increase access to innovative rehabilitation technology and assist more individuals in regaining balance and independence [3] Group 3: Company Background - Ekso Bionics specializes in developing exoskeleton solutions that enhance human strength, endurance, and mobility across medical and industrial applications, focusing on improving health and quality of life [4] - MediTouch is committed to creating advanced rehabilitation solutions for various healthcare settings, empowering clinicians and patients with effective rehabilitation tools [5]

Core Viewpoint - Ekso Bionics (EKSO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to institutional investors adjusting their valuations, resulting in buying or selling actions that affect stock prices [4]. Company Performance Indicators - Ekso Bionics is projected to earn -$0.92 per share for the fiscal year ending December 2025, showing no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for Ekso Bionics has increased by 21.4%, reflecting a positive trend in earnings outlook [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Ekso Bionics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

Core Insights - Several stocks experienced significant movements in after-hours trading, influenced by earnings announcements and financing updates, particularly in the healthcare and biotech sectors [1] Company Summaries - **PACS Group Inc. (PACS)**: The stock surged 45.48% to $24.48 after a 16.63% increase during regular trading, closing at $16.83. The company reported Q3 net income of $52.4 million ($0.32 per share), up from $15.6 million ($0.10 per share) a year ago. Revenue increased to $1.345 billion from $1.026 billion. For fiscal 2025, PACS expects revenue between $5.25 billion and $5.35 billion, with adjusted EBITDA projected at $480 million to $490 million [2] - **Zynex, Inc. (ZYXI)**: The stock rose 4.49% after hours to $0.58, following a 32.14% gain during regular trading. The company reported a net loss of $42.9 million ($1.42 per share) for the quarter ended September 30, 2025, compared to a net income of $2.3 million ($0.07 per share) in the same period last year. Net revenue fell to $13.4 million from $50.0 million [3] - **Genenta Science S.p.A. (GNTA)**: The stock increased 7.34% after hours to $1.90, recovering from an 11.06% decline to $1.77. Last month, the company announced a securities purchase agreement for 4,285,715 American Depositary Shares at $3.50 per ADS, raising approximately $15.0 million before fees and expenses [4] - **Ekso Bionics Holdings, Inc. (EKSO)**: The stock gained 4.22% in after-hours trading to $4.20, after closing at $4.03, down 3.47% earlier in the day. In late October, the company disclosed a registered direct offering of 769,490 shares priced at $4.81 per share [5] - **Nutex Health Inc. (NUTX)**: The stock advanced 9.64% after hours to $123.00, following a 13.09% rise during regular trading to $112.19. The company reported Q3 net income of $55.4 million, reversing a net loss of $8.8 million in the same period last year. Revenue climbed to $267.8 million, up from $78.8 million, marking a 239.9% increase [6]